Attorneys and journalists: Newsroom Tools Search
perfectplaintiff Find an attorney
  1. Home
  2. Mass torts
  3. Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation

Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation

MDL No. 3094 · Products Liability · U.S. District Court, Eastern District of Pennsylvania

What are these lawsuits about?

All actions share common issues of fact regarding whether defendants knew or should have known that their GLP-1 RA products can cause gastroparesis and other gastrointestinal injuries, whether defendants adequately warned plaintiffs or their prescribing physicians about the alleged dangers of these products, and whether defendants made false, misleading, or incomplete representations regarding the safety of these products.

Judicial Panel on Multidistrict Litigation, transfer order of 2 February 2024 in MDL No. 3094 Sourced

This is the Panel's own description, quoted word for word from the order that created the litigation. It describes what the lawsuits allege, not what has been proved, and the litigation may have changed since.

The basics

Name on the docketIN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation
Multidistrict litigation numberMDL No. 3094
CourtU.S. District Court, Eastern District of Pennsylvania
JudgeKaren S. Marston (U.S. District Judge)
Master docket number2:24-md-3094
Court filingsFiled under the master docket number above. How to look up the filings
CategoryProducts Liability
Filed with the Panel1 December 2023
Sent to this court2 February 2024
StatusPending on the Panel's report of 2 November 2026

These details are as the Judicial Panel on Multidistrict Litigation lists them.

How fast have lawsuits been filed?

A year-by-year count is not available for this litigation. We show one only when the federal case database's total for the docket is close to the Panel's, and here it is not, or the litigation is too new.

Common questions

How many lawsuits are pending in the Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation?

4,082 lawsuits were pending as of 2 November 2026, out of 4,196 filed or transferred into the litigation since it began, according to the Judicial Panel on Multidistrict Litigation (sourced).

What is the Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation about?

In the order that created the litigation, the Judicial Panel on Multidistrict Litigation described it this way: "All actions share common issues of fact regarding whether defendants knew or should have known that their GLP-1 RA products can cause gastroparesis and other gastrointestinal injuries, whether defendants adequately warned plaintiffs or their prescribing physicians about the alleged dangers of these products, and whether defendants made false, misleading, or incomplete representations regarding the safety of these products." That describes what the lawsuits allege, not what has been proved.

Which court and judge are handling the Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation?

It is MDL No. 3094, before Karen S. Marston (U.S. District Judge) in the U.S. District Court, Eastern District of Pennsylvania. The master docket number is 2:24-md-3094.

Is the Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation a class action?

It is a multidistrict litigation, which is different from a class action. Each lawsuit in a multidistrict litigation stays a separate case with its own outcome; the cases are gathered before one judge for pretrial work. A multidistrict litigation can include class actions among its cases.

Has the Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation settled?

We found no settlement amount for this litigation in company filings with the Securities and Exchange Commission. That does not mean none exists: private companies and most foreign companies do not file such reports, and many settlements are confidential. The litigation was still on the Panel's list of pending litigations on 2 November 2026, which means it had not been closed.

Has a settlement amount been disclosed?

We found no settlement amount for this litigation in company filings with the Securities and Exchange Commission. That does not mean none exists: private companies and most foreign companies do not file such reports, and many settlements are confidential. We do not estimate settlement amounts. Amounts that have been disclosed for other litigations are in the settlement tracker.

How has the number of pending lawsuits moved?

On 3 November 2025, 2,914 lawsuits were pending. On 2 November 2026, 4,082 were (sourced from the Panel's monthly reports).

Report dateLawsuits pending
3 November 20252,914
2 December 20252,947
5 January 20263,063
2 February 20263,191
2 March 20263,363
1 April 20263,546
1 May 20263,636
1 June 20263,763
1 July 20263,848
3 August 20263,928
1 September 20264,022
1 October 20264,025
2 November 20264,082

A month is missing where we could not read every row of that month's report. Every litigation is compared in the mass tort tracker.

How long do litigations like this last?

We do not estimate when this litigation will end; we make no estimates about any named litigation. For a sense of scale, this is how long finished litigations lasted, from the first case filed to the last case closed, grouped by how many cases they held.

How long finished litigations lastedComputed

Size of litigationFinished litigations measuredMedian lengthMiddle half lasted
100 to 999 cases438 years5.5 to 9.5 years
1,000 to 9,999 cases1011 years9.5 to 12.5 years
10,000 cases or moreToo few to compare——

A litigation counts as finished when no case carrying its docket number is still pending. A group is shown only when at least ten finished litigations can be measured.

Related litigations

Other products liability litigations

Others in the same court

All pending litigations

Sources

Last updated 18 November 2026. That is the date we last retrieved the source files below.

Download the figures behind this page (CSV). Every row gives its label and its source. More files are in the data catalogue.

  • U.S. Judicial Panel on Multidistrict Litigation, MDL Statistics Report: pending MDL dockets File retrieved 18 November 2026 from jpml.uscourts.gov. File fingerprint 2854e718c8e5.
  • U.S. Judicial Panel on Multidistrict Litigation, MDL Statistics Report: pending MDL dockets File retrieved 16 November 2026 from jpml.uscourts.gov. File fingerprint 4c8c598b9758.
  • U.S. Judicial Panel on Multidistrict Litigation, MDL Statistics Report: pending MDL dockets File retrieved 16 November 2026 from jpml.uscourts.gov. File fingerprint 02acf48f3753.
  • U.S. Judicial Panel on Multidistrict Litigation, MDL Statistics Report: pending MDL dockets File retrieved 16 November 2026 from jpml.uscourts.gov. File fingerprint 06530a1c2eba.
  • U.S. Judicial Panel on Multidistrict Litigation, MDL Statistics Report: pending MDL dockets File retrieved 16 November 2026 from jpml.uscourts.gov. File fingerprint f9835afbad7a.
  • U.S. Judicial Panel on Multidistrict Litigation, MDL Statistics Report: pending MDL dockets File retrieved 16 November 2026 from jpml.uscourts.gov. File fingerprint beecdb1fcbd3.
  • U.S. Judicial Panel on Multidistrict Litigation, MDL Statistics Report: pending MDL dockets File retrieved 16 November 2026 from jpml.uscourts.gov. File fingerprint 68ffe884f3c4.
  • U.S. Judicial Panel on Multidistrict Litigation, MDL Statistics Report: pending MDL dockets File retrieved 16 November 2026 from jpml.uscourts.gov. File fingerprint 8d89078404ff.
  • U.S. Judicial Panel on Multidistrict Litigation, MDL Statistics Report: pending MDL dockets File retrieved 16 November 2026 from jpml.uscourts.gov. File fingerprint 6bdcea2af28e.
  • U.S. Judicial Panel on Multidistrict Litigation, MDL Statistics Report: pending MDL dockets File retrieved 16 November 2026 from jpml.uscourts.gov. File fingerprint 1aa2181acd5a.
  • U.S. Judicial Panel on Multidistrict Litigation, MDL Statistics Report: pending MDL dockets File retrieved 16 November 2026 from jpml.uscourts.gov. File fingerprint 1c5e7f62c95a.
  • U.S. Judicial Panel on Multidistrict Litigation, MDL Statistics Report: pending MDL dockets File retrieved 16 November 2026 from jpml.uscourts.gov. File fingerprint 1113fa70c312.
  • U.S. Judicial Panel on Multidistrict Litigation, MDL Statistics Report: pending MDL dockets File retrieved 16 November 2026 from jpml.uscourts.gov. File fingerprint 9e1e4117add7.
  • Federal Judicial Center Integrated Database (civil, 1988 forward) File retrieved 18 November 2026 from fjc.gov. File fingerprint 74405231a9a3.
Where each sourced figure appears in the source (2)
  • Actions pending, Multidistrict litigation (all types): Distribution of Pending MDL Dockets by Actions Pending, row 'MDL -3094', column 'Actions Now Pending'. As published: 4,082
  • Total actions to date, Multidistrict litigation (all types): Distribution of Pending MDL Dockets by Actions Pending, row 'MDL -3094', column 'Total Actions (Historical)'. As published: 4,196

The full address of every source file is on the sources page. Found something wrong? See corrections and removal requests. How figures are labelled and calculated is in the methodology.